Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.37 |
| ▸ | WNT3A | P56704 | 1/20 | 0.37 |
| ▸ | EDNRB | P24530 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644934 | 0.95 | KIF11 (0.53) | KIF11KCNH2CTNNB1WNT3AEDNRB | |
| SCHEMBL647538 | 0.94 | KIF11 (0.57) | KIF11KCNH2EDNRBRAB9AMCHR1 | |
| SCHEMBL646310 | 0.92 | KIF11 (0.63) | KIF11KCNH2RAB9AMCHR1ALDH1A1 | |
| SCHEMBL644717 | 0.91 | KIF11 (0.55) | KIF11KCNH2CTNNB1WNT3AEDNRB | |
| SCHEMBL645338 | 0.91 | KIF11 (0.66) | KIF11KCNH2CTNNB1WNT3AEDNRB | |
| SCHEMBL645151 | 0.90 | KIF11 (0.59) | KIF11KCNH2RAB9AALDH1A1 | |
| SCHEMBL645407 | 0.90 | KIF11 (0.66) | KIF11KCNH2RAB9AALDH1A1 | |
| SCHEMBL645780 | 0.89 | KIF11 (0.56) | KIF11KCNH2RAB9AALDH1A1 | |
| SCHEMBL643497 | 0.89 | KIF11 (0.65) | KIF11KCNH2RAB9AMCHR1ALDH1A1 | |
| SCHEMBL645507 | 0.89 | KIF11 (0.54) | KIF11KCNH2CTNNB1WNT3ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119678-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110230550-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2011-09-22 | — | — | US | disclosed |
| US-7919524-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230550-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | KIF11 824/4885KCNH2 2582/4885CTNNB1 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.